AZURRX BIOPHARM (NASDAQ:AZRX)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Thursday. They presently have a $8.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 124.72% from the company’s current price.

AZURRX BIOPHARM (NASDAQ:AZRX) traded down 8.01% during trading on Thursday, hitting $3.56. 113,719 shares of the stock traded hands. The stock’s market cap is $39.99 million. AZURRX BIOPHARM has a 52-week low of $3.07 and a 52-week high of $5.60. The stock has a 50 day moving average price of $3.91 and a 200-day moving average price of $3.85.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at

In related news, major shareholder Pelican Partners Llc sold 160,000 shares of the stock in a transaction dated Friday, June 30th. The stock was sold at an average price of $3.19, for a total transaction of $510,400.00. Following the transaction, the insider now directly owns 1,787,796 shares in the company, valued at $5,703,069.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

An institutional investor recently raised its position in AZURRX BIOPHARM stock. IHT Wealth Management LLC boosted its position in AZURRX BIOPHARM (NASDAQ:AZRX) by 15.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,498 shares of the company’s stock after buying an additional 464 shares during the period. IHT Wealth Management LLC’s holdings in AZURRX BIOPHARM were worth $486,000 as of its most recent filing with the SEC. 5.74% of the stock is owned by institutional investors.


AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.

Receive News & Stock Ratings for AZURRX BIOPHARM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AZURRX BIOPHARM and related stocks with our FREE daily email newsletter.